•Executive Summary
oMarket Overview
•Market Landscape
oMarket ecosystem
oMarket characteristics
oValue chain analysis
•Market Sizing
oMarket definition
oMarket segment analysis
oMarket size 2019
oMarket outlook: Forecast for 2019 - 2024
•Five Forces Analysis
oFive Forces Summary
oBargaining power of buyers
oBargaining power of suppliers
oThreat of new entrants
oThreat of substitutes
oThreat of rivalry
oMarket condition
•Market Segmentation by Product
oMarket segments
oComparison by Product
omAbs - Market size and forecast 2019-2024
oHuman insulin - Market size and forecast 2019-2024
oErythropoeitin - Market size and forecast 2019-2024
oClotting factors - Market size and forecast 2019-2024
oOthers - Market size and forecast 2019-2024
oMarket opportunity by Product
•Market segmentation by Therapy Area
oMarket segments
oMetabolic and endocrine disorders
oHematopoiesis
oFertility
oCancer
oAutoimmune diseases
oInfectious diseases
oProtein vaccine
•Market segmentation by Protein Function
oMarket segments
oEnzymatic and regulatory activity
oSpecial targeting activity
oVaccines
oProtein diagnostics
•Customer Landscape
•Geographic Landscape
oGeographic segmentation
oGeographic comparison
oNorth America - Market size and forecast 2019-2024
oEurope - Market size and forecast 2019-2024
oAPAC - Market size and forecast 2019-2024
oSouth America - Market size and forecast 2019-2024
oMEA - Market size and forecast 2019-2024
oKey leading countries
oMarket opportunity by geography
oMarket drivers
oMarket challenges
oMarket trends
•Vendor Landscape
oOverview
oLandscape disruption
•Vendor Analysis
oVendors covered
oMarket positioning of vendors
oAbbVie Inc.
oAmgen Inc.
oAstraZeneca Plc
oEli Lilly and Co.
oF. Hoffmann-La Roche Ltd.
oJohnson & Johnson
oMerck & Co. Inc.
oNovo Nordisk AS
oPfizer Inc.
oSanofi
•Appendix
oScope of the report
oCurrency conversion rates for US$
oResearch methodology
oList of abbreviations

Exhibit
•1: Key Finding 1
•2: Key Finding 2
•3: Key Finding 3
•4: Key Finding 5
•5: Key Finding 6
•6: Key Finding 7
•7: Key Finding 8
•8: Parent market
•9: Market characteristics
•10: Offerings of vendors included in the market definition
•11: Market segments
•12: Global - Market size and forecast 2019 - 2024 ($ billion)
•13: Global market: Year-over-year growth 2019 - 2024 (%)
•14: Five forces analysis 2019 & 2024
•15: Bargaining power of buyers
•16: Bargaining power of suppliers
•17: Threat of new entrants
•18: Threat of substitutes
•19: Threat of rivalry
•20: Market condition - Five forces 2019
•21: Product - Market share 2019-2024 (%)
•22: Comparison by Product
•23: mAbs - Market size and forecast 2019-2024 ($ billion)
•24: mAbs - Year-over-year growth 2019-2024 (%)
•25: Human insulin - Market size and forecast 2019-2024 ($ billion)
•26: Human insulin - Year-over-year growth 2019-2024 (%)
•27: Erythropoeitin - Market size and forecast 2019-2024 ($ billion)
•28: Erythropoeitin - Year-over-year growth 2019-2024 (%)
•29: Clotting factors - Market size and forecast 2019-2024 ($ billion)
•30: Clotting factors - Year-over-year growth 2019-2024 (%)
•31: Others - Market size and forecast 2019-2024 ($ billion)
•32: Others - Year-over-year growth 2019-2024 (%)
•33: Market opportunity by Product
•34: Customer landscape
•35: Market share by geography 2019-2024 (%)
•36: Geographic comparison
•37: North America - Market size and forecast 2019-2024 ($ billion)
•38: North America - Year-over-year growth 2019-2024 (%)
•39: Europe - Market size and forecast 2019-2024 ($ billion)
•40: Europe - Year-over-year growth 2019-2024 (%)
•41: APAC - Market size and forecast 2019-2024 ($ billion)
•42: APAC - Year-over-year growth 2019-2024 (%)
•43: South America - Market size and forecast 2019-2024 ($ billion)
•44: South America - Year-over-year growth 2019-2024 (%)
•45: MEA - Market size and forecast 2019-2024 ($ billion)
•46: MEA - Year-over-year growth 2019-2024 (%)
•47: Key leading countries
•48: Market opportunity by geography ($ billion)
•49: Impact of drivers and challenges
•50: Vendor landscape
•51: Landscape disruption
•52: Industry risks
•53: Vendors covered
•54: Market positioning of vendors
•55: AbbVie Inc. - Overview
•56: AbbVie Inc. - Business segments
•57: AbbVie Inc. - Key offerings
•58: AbbVie Inc. - Key customers
•59: AbbVie Inc. - Segment focus
•60: Amgen Inc. - Overview
•61: Amgen Inc. - Business segments
•62: Amgen Inc. - Key offerings
•63: Amgen Inc. - Key customers
•64: Amgen Inc. - Segment focus
•65: AstraZeneca Plc - Overview
•66: AstraZeneca Plc - Business segments
•67: AstraZeneca Plc - Key offerings
•68: AstraZeneca Plc - Key customers
•69: AstraZeneca Plc - Segment focus
•70: Eli Lilly and Co. - Overview
•71: Eli Lilly and Co. - Business segments
•72: Eli Lilly and Co. - Key offerings
•73: Eli Lilly and Co. - Key customers
•74: Eli Lilly and Co. - Segment focus
•75: F. Hoffmann-La Roche Ltd. - Overview
•76: F. Hoffmann-La Roche Ltd. - Business segments
•77: F. Hoffmann-La Roche Ltd. - Key offerings
•78: F. Hoffmann-La Roche Ltd. - Key customers
•79: F. Hoffmann-La Roche Ltd. - Segment focus
•80: Johnson & Johnson - Overview
•81: Johnson & Johnson - Business segments
•82: Johnson & Johnson - Key offerings
•83: Johnson & Johnson - Key customers
•84: Johnson & Johnson - Segment focus
•85: Merck & Co. Inc. - Overview
•86: Merck & Co. Inc. - Business segments
•87: Merck & Co. Inc. - Key offerings
•88: Merck & Co. Inc. - Key customers
•89: Merck & Co. Inc. - Segment focus
•90: Novo Nordisk AS - Overview
•91: Novo Nordisk AS - Business segments
•92: Novo Nordisk AS - Key offerings
•93: Novo Nordisk AS - Key customers
•94: Novo Nordisk AS - Segment focus
•95: Pfizer Inc. - Overview
•96: Pfizer Inc. - Business segments
•97: Pfizer Inc. - Key offerings
•98: Pfizer Inc. - Key customers
•99: Pfizer Inc. - Segment focus
•100: Sanofi - Overview
•101: Sanofi - Business segments
•102: Sanofi - Key offerings
•103: Sanofi - Key customers
•104: Sanofi - Segment focus
•105: Currency conversion rates for US$
•106: Research Methodology
•107: Validation techniques employed for market sizing
•108: Information sources
•109: List of abbreviations

Companies Mentioned
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co. Inc.
• Novo Nordisk AS
• Pfizer Inc.
• Sanofi